Skip to content

Human Efficacy Evaluation Test of SUNFLYING BABY Children's Moisturizing and Safety face cream.

Human Efficacy Evaluation Test of SUNFLYING BABY Children's Moisturizing and Safety face cream.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500096645
Enrollment
Unknown
Registered
2025-01-27
Start date
2024-10-30
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

none

Interventions

Experiment 1 Facial Test Group:Facial samples are used, but arm samples are not used
Experiment 1 Facial Control Group:Do not use samples on the face, use samples on one arm, and do not use samples on the other arm.
Experiment 2 Arm Test Group (Facial control group in Experiment 1):Single arm usage sample
Experiment 2 Arm Control Group (Facial control group in Experiment 1):The other arm does not use the sample

Sponsors

Dematology Hospital of Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. 18-50 years old, Asian (China), healthy female/male; 2. Dry and sensitive skin; 3. Lactic acid stinging positive; 4. Facial redness and dryness; 5. The skin of the arm testing area is intact without any damage, and there are no skin related diseases; 6. The skin types of the subjects are type I, II, and III, which means they are sensitive to sunlight or ultraviolet radiation and are prone to sunburn but less prone to pigmentation after exposure. 7. Those who can understand the experimental process, voluntarily participate in the experiment, and sign a written informed consent form.

Exclusion criteria

Exclusion criteria: 1. Individuals who have used any topical medication on the test site within the past two months; 2. Those who have used antihistamines in the past week or immunosuppressants in the past month; 3. Patients with inflammatory skin diseases who have not recovered clinically; 4. Insulin dependent diabetes patients; 5. Patients with asthma or other chronic respiratory diseases undergoing treatment; 6. Individuals who have received anti-cancer chemotherapy within the past six months; 7. Patients with immunodeficiency or autoimmune diseases; 8. Women who plan to become pregnant, pregnant, or breastfeeding; 9. There are obvious scars, pigmentation, atrophy, erythema, sunspots, wounds, wear and tear on or near the skin testing site 10. Tattoos or other defects that affect the judgment of test results; 11. Those who have received medical beauty treatments such as photon rejuvenation, laser, or other facial beauty methods that may affect their skin condition in the past three months; 12. Individuals who have participated in facial trials, oral medication trials, or other clinical trials within the past 2 months; 13. Individuals with high physical sensitivity, known to be allergic to ingredients in cosmetics or daily chemical products, alcohol, rubber, or drugs; 14. Those who need to be exposed to outdoor sunlight for a long time due to work or other reasons; 15. Individuals with other iatrogenic issues that may affect the test results (such as a history of coagulation dysfunction, severe hyperglycemia, hypertension, hyperlipidemia, mental illness, or other major illnesses); 16. Non voluntary participants or those who are unable to complete the prescribed experimental content as required.

Design outcomes

Primary

MeasureTime frame
Subject self-assessment;Skin ultrasound testing;Transdermal moisture loss measurement;Transdermal moisture loss measurement;Measurement of moisture content in the stratum corneum;Antera 3D image acquisition;

Secondary

MeasureTime frame
Researchers' Visual Assessment;Lactic acid stinging test;Researchers' Visual Assessment;

Countries

China

Contacts

Public ContactYe Li

Dematology Hospital of Southern Medical University

dlpfbyy@163.com+86 20 83028375

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026